nuclear run-on (nro) is a method that measures transcriptional activity via the quantification of biochemically labeled nascent rna molecules derived from nuclear isolates. Widespread use of this technique has been limited because of its technical difficulty relative to steady-state total mrna analyses. Here we describe a detailed protocol for the quantification of transcriptional activity in human cell cultures. nuclei are first isolated and nro transcription is performed in the presence of bromouridine. labeled nascent transcripts are purified by immunoprecipitation, and transcript levels are determined by reverse-transcription quantitative pcr (rt-qpcr). Data are then analyzed using standard techniques described elsewhere. this method is rapid (the protocol can be completed in 2 d) and cost-effective, exhibits negligible detection of background noise from unlabeled transcripts, requires no radioactive materials and can be performed from as few as 500,000 nuclei. It also takes advantage of the high sensitivity, specificity and dynamic range of rt-qpcr.
IntroDuctIon
Transcription is the process by which a transient RNA transcript is generated through the copying of a complementary genomic DNA template. As such, transcription constitutes the first stage of gene expression and is therefore a fundamental cellular function. The vast majority of gene expression studies use steady-state total mRNA measurements (e.g., semiquantitative RT-PCR, RT-qPCR, microarray or RNA sequencing) [1] [2] [3] [4] . These methods provide a snapshot of transcript abundance in the cell. However, steady-state transcript levels are a function of both transcriptional synthesis and post-transcriptional degradation. With conventional gene expression analysis, it is therefore impossible to distinguish transcriptional from post-transcriptional gene regulatory effects.
NRO analysis is a biochemical method for quantifying changes in transcriptional activity in cultured cells [5] [6] [7] [8] . Cell nuclei are first collected by gentle lysis of the plasma membrane and low-speed centrifugation. Maintaining nuclear preparations at low temperature ensures that the nuclear membrane remains intact and that active RNA polymerase II (RNAPII), and other associated proteins, remains paused on the genome. Subsequently, transcription is allowed to continue by warming the nuclear samples and allowing RNAPII activity to resume. This in vitro NRO transcription reaction is performed in the presence of labeled ribonucleotide precursors. Incorporation of labeled nucleotides into nascent transcripts (NRO-RNAs) enables their specific quantification against a background of unlabeled nuclear RNAs. Changes in NRO-RNA abundance (determined by blotting, nucleic acid amplification, microarray or high-throughput sequencing techniques) are therefore a direct reflection of transcriptional activity.
Classically, NRO has been performed using 32 P-containing UTP to label nascent RNA. Post-NRO samples are blotted onto membranes and nascent transcription is visualized by autoradiography [5] [6] [7] [8] . Nonradioactive variants that use biotin-16-aminoallyluridine or bromouridine have since been reported 9 , with nascent transcripts quantified by RT-qPCR 10 or semiquantitative RT-PCR using fluorescent primers 11 .
The NRO assay is technically more difficult and laborintensive than conventional steady-state (total mRNA) gene expression analysis, which has likely limited its widespread use. Typically, NRO has required large number of cells (e.g., at least 6 million cells in 15-cm 2 plates 12 ), meaning that analysis of rare samples or small subsets of sorted cells may not be possible. Furthermore, a number of specific technical hurdles can potentially confound NRO analysis, including inappropriate qPCR primer design, qPCR data normalization, changes in nuclear RNA content between experimental groups, high background signal and unequal label incorporation between samples. Here we describe a highly optimized and validated NRO protocol based on bromouridine immunocapture and RT-qPCR that enables facile, rapid, reproducible, cheap and readily automatable detection of nascent transcription in human cell cultures (Fig. 1) . We have used this protocol to investigate MYC-mediated transcriptional regulation of long noncoding RNAs (lncRNAs) 13 .
Development of the protocol
The current protocol is an improved version of a previous method 10 . The protocol was modified to simplify several steps, limit sample handling time, reduce background binding and improve reproducibility. Each step of the protocol was validated and/or optimized (Supplementary Results). First, the isolation of intact nuclei was demonstrated in HEK293T and P493-6 cells ( Supplementary Fig. 1 ). By using multiple approaches, we showed that the protocol specifically detects nascent transcription ( Supplementary Fig. 2 ). We also determined suitable ranges for input numbers of nuclei and input nuclear RNA in the immunoprecipitation stage (Supplementary Fig. 2) , and the performance of three different anti-bromouridine antibodies was directly compared (Supplementary Fig. 3 ). (Primer-binding locations are shown in Supplementary Fig. 4 for the RT-qPCR assays used for protocol validation.) By using a dual spike-in strategy (Box 1), the protocol was found to detect negligible background unlabeled nuclear RNA (Supplementary Fig. 5 ).
Terminating the NRO reaction. Previously, we terminated the reaction by incubating it with DNase I followed by a second incubation with proteinase K 10 . However, strong association between proteins and genomic DNA inhibits complete digestion, and proteolysis to remove these proteins results in loss of DNase I activity.
We therefore chose to simplify this stage of the protocol by directly extracting RNA 13 . The use of extraction buffers that contain chaotropic salts such as guanidinium isothiocyanate allows for the disruption of protein-DNA interactions while simultaneously ensuring rapid and complete termination of the NRO reaction. To stop the NRO reaction and to collect NRO-RNA, we have used the Maxwell 16 RNA extraction system from Promega. This method is rapid (~50 min) and consistent between samples, and it includes a rigorous DNA removal step. Alternatively, other automated or manual RNA extraction methodologies are suitable, such as MEGA clear/TRIzol/RNeasy followed by a separate DNase I step. The preparation of pure RNA samples allows for clean immunoprecipitation pull-downs with low background binding. It is important to measure the concentration of nuclear RNA at this stage, as this value may vary between experimental groups. Measuring the concentration in each sample of nuclear RNA also allows the inter-and intra-experimental standardization of input RNA at the immunoprecipitation stage.
Immunoprecipitation. Agarose beads conjugated to anti-BrdU antibodies have been used in multiple studies reporting NRO or global run-on sequencing (GRO-seq) data 12, 14 . In this protocol, we have used superparamagnetic beads derivatized with protein G in order to precipitate bromouridylated RNAantibody complexes. Magnetic handling offers a number of advantages over agarose slurry-based methods: (i) complete wash buffer removal with minimal sample loss; (ii) low background binding; (iii) fast diffusion kinetics and therefore reduced wash times as a result of defined bead sizes; and (iv) magnetic separation steps that are readily automatable. Some GRO-seq protocols use a triple-selection strategy to massively enrich for labeled NRO-RNAs 12 . If necessary, additional rounds of immunoprecipitation can be used to enrich for labeled transcripts and to reduce background by repeating PROCEDURE Steps 16-43.
Applications of NRO-RT-qPCR
NRO RT-qPCR is suitable for analyzing any change in transcriptional activity (e.g., regulation of specific promoters by transcription factors, noncoding RNAs or small-molecule interactions) and for the reliable determination of promoter elements. Moreover, NRO also enables the investigation of phenomena such as promoter bidirectional transcription 12 , enhancer transcription [14] [15] [16] [17] and the differential regulation of transcription at the initiation and elongation stages (e.g., by polymerase pausing) [18] [19] [20] . NRO is particularly useful for distinguishing transcriptional from post-transcriptional gene regulatory mechanisms. For example, a plethora of studies have shown that small RNA molecules can induce transcriptional gene silencing (TGS) via a process analogous to RNAi (or post-TGS, PTGS) [21] [22] [23] [24] . NRO analysis has been used to distinguish the novel TGS phenomena from the much more commonly reported PTGS effects. Similarly, long noncoding RNAs (lncRNAs) have been implicated in the epigenetic control of gene expression 25 . NRO can therefore be used to demonstrate the gene regulatory effects of specific lncRNAs at the level of transcription 13 .
Advantages of the NRO-RT-qPCR protocol are that it is rapid, low cost, requires relatively small amounts of starting material and does not use radioactive materials. In addition, RT-qPCR is an ideal method for analyzing NRO-RNA levels on account of its widespread adoption in research laboratories, high specificity and wide dynamic range (typically >6 log). There is therefore a need for RT-qPCR-based NRO protocols that are suitable for addressing single-gene questions, and that are not technically and economically cumbersome or prohibitive. A disadvantage of the protocol is that it is limited to the study of only a small number of genes. Genome-wide methods for analysis of transcription are discussed below.
Alternatives to NRO-qPCR
Quantification of unspliced pre-mRNA. This approach has been proposed as a simple alternative, and an indirect method for Box 1 | Generation of spike-in control oligonucleotides (optional) • tIMInG 6 h Spike-in oligonucleotides can be used to control for changes in nuclear RNA content and to determine signal:noise ratios in experimental samples. The following steps describe how to generate synthetic transcripts with nonmammalian sequences by in vitro transcription using a T7 polymerase that is capable of incorporating bromouridine into its RNA products. 1. Templates for each spike-in oligonucleotide are generated from the same plasmid (psiCHECK-2) in two separate PCRs using different primer pairs (RLuc T7-FWD/ RLuc T7-REV or FLuc T7-FWD/FLuc T7-REV). Prepare T7 transcription templates in two separate PCR amplifications using the following reaction cocktail: determining transcriptional activity 26 . Although this approach is facile, it is subject to its own problems. Specifically, multiple studies have demonstrated that PTGS events can occur in the nucleus [27] [28] [29] , meaning that changes in pre-mRNA levels may not necessarily reflect changes in transcriptional activity. Furthermore, such an approach is also limited to intron-containing genes.
Combination of NRO with deep sequencing. These methodologies include GRO-seq 12, 14 and more recently precision run-on followed by sequencing 30 . These techniques have enabled fundamental new insights into the process of transcription, such as the detection of widespread divergent transcription from human promoters and high-resolution mapping of polymerase pause sites. However, in many cases, genome-wide analysis is unnecessary or uneconomical; a discussion of the relative costs of NRO-RT-qPCR and GRO-seq is included in the Supplementary Discussion. In some cases, it may be useful to use NRO-RT-qPCR as a quality control tool during the preparation of GRO-seq libraries. Similarly, GRO-seq results may require validation on a gene-bygene basis. In these cases, a complementary method for analyzing a small number of genes is desirable.
Metabolic labeling. This strategy consists of the addition of modified ribonucleotide precursors to the medium of cells in culture. Labeled RNA precursors are taken up by cells and incorporated into nascent transcripts. Labeled transcripts are then purified and quantified. A disadvantage of metabolic labeling is that incorporation of the labeled nucleotide may have adverse effects on cell physiology. For example, culturing cells for an extended period of time in the presence of 4-thiouridine or 5-ethynyluridne results in inhibition of cell growth 31 . Furthermore, 4-thiouridine can bind to guanine, which introduces base changes in label-containing nascent transcripts 32 . In the case of both 4-thiouridine and 5-ethynyluridine, additional chemical reaction steps are required before nascent transcript purification and quantification (thiol-biotinylation 33 and azide-biotin cycloaddition click chemistry 34 , respectively).
In contrast, metabolic labeling with 5-bromouridine does not affect cell growth, it does not introduce base changes within a typical experimental time frame and it does not require chemical addition of an additional moiety for affinity purification 31 . This approach has also been combined with high-throughput sequencing as in the cases of bromouridine sequencing, bromouridinechase sequencing 35, 36 and 5′-bromouridine immunoprecipitation followed by sequencing 31, 37 . An advantage of these approaches is that, in addition to labeling nascent RNA, global transcript stability can also be determined using a pulse-chase strategy (chasing with unlabeled uridine). A variety of methods have been used to introduce labeled nucleotides into cells; microinjection, permeabilization, transfection and osmotic shock have all been used to facilitate bromouridine uptake [38] [39] [40] [41] . The issues surrounding bromouridine uptake add additional experimental complexity and potential confounding factors, which are not applicable to NRO methodologies.
Experimental design Primer design.
Correct qPCR assay design is crucial to the success of the NRO technique. As with conventional qPCR, primers should be 18-22 nt in length, have a GC content of 40-60%, T m values of ~60 °C and they should produce a short (50-150 bp) amplicon.
Of key importance is the observation that nascent NRO-RNAs produced by run-on transcription are ectopic transcripts lacking splicing or polyadenylation 12 (Supplementary Fig. 6a ). As a result, NRO RT should be performed using random primers (or strand-specific primers for distinguishing between overlapping sense and antisense transcripts), whereas the use of oligo-dT primers should be avoided. Similarly, several conventional qPCR assay configurations for measuring steady-state mature mRNA transcript levels (frequently employed in commercially available assays) are unsuitable for detecting nascent transcripts. Inappropriate designs include: (i) the use of primers placed in different exons that are separated by large distances (kilobases) in genomic space but only short distances (~100 bp) in the spliced transcript, and (ii) primers or probe complementary to exon-exon junctions (Supplementary Fig. 6b ). Suitable designs for NRO-RT-qPCR therefore include: (i) primers that bind within the same exon, (ii) primers within the same intron or (iii) primer sequences spanning an intron-exon boundary (Supplementary Fig. 6b ). In fact, primers that span intron-exon boundaries may be preferable for NRO-RT-qPCR in many cases, as this design excludes the amplification of contaminating processed mRNA. Importantly, all NRO-RT-qPCR assays have the potential to amplify genomic DNA, and the removal of DNA background during nuclear RNA preparation is therefore essential.
To investigate transcriptional pausing, NRO-RT-qPCR assays can be designed to amplify distinct regions within the same gene (specifically the 5′ terminus and the gene body, respectively). Changes in transcriptional initiation with a constant rate of elongation would be expected to affect the signal from both assays equivalently. Conversely, changes in transcriptional elongation (e.g., after the release of paused polymerase) would be expected to result in differences in NRO signal from the gene body but not at the 5′ terminus. To perform these analyses, it is important that the length of NRO-RNAs be restricted to ~200-300 nt to ensure that the NRO-RNAs do not extend indefinitely toward the end of the gene. This can be accomplished by ensuring that the concentration of one ribonucleotide in the NRO reaction (typically CTP) is limiting (CTP restriction is also commonly used in GRO-seq methodologies 12 ).
Replicates. Typically, one or more experimental conditions are compared with untreated cultures. Three replicate cultures of each condition are sufficient in most cases, although a power analysis may be required to determine the sample size needed to achieve statistical significance.
Controls. qPCRs lacking template cDNA (no-template controls) should be included to monitor possible reagent contamination, which is typically a result of amplicon carryover. Similarly, performing the RT reaction without enzyme (RT− control) can be used to monitor gDNA contamination. We have routinely observed no amplification in RT− control samples consistent with complete gDNA removal (Supplementary Fig. 7 ).
Reference genes. Nascent gene-of-interest transcription is normalized to a reference (housekeeping) gene to control for equal sample loading between reactions as with steady-state total mRNA analysis. Normalization to the geometric mean of multiple reference genes is recommended in order to minimize biases associated with the variability of any one gene 42 . Notably, we have observed that reference genes that are suitable for total mRNA analysis are not necessarily suitable for NRO-RT-qPCR. For example, the ribosomal protein L10 (RPL10) mRNA is highly abundant in total RNA extracts, but it is detected at low levels by NRO (data not shown). As a result, the low rate of transcription and high transcript stability make RPL10 an excellent reference gene for steady-state total mRNA expression studies and a poor reference gene for NRO-RT-qPCR.
In 2009, the MIQE (minimum information for publication of quantitative real-time PCR experiments) guidelines were established to promote consistency and transparency in gene expression studies 43, 44 . To date, these guidelines have not been applied to NRO experiments.
To conform to community standards, and to help facilitate research in this area, we provide details of 12 validated and MIQE-compliant RT-qPCR assays for human NRO-RNA reference genes: ACTB, B2M, GAPDH, GUSB, HPRT1, PPIA, RPL10, RPLP0, TBP, TUBB, UBC and YWHAZ. Primer sequences are shown in Table 1 , and additional validation data are shown in Supplementary Figure 8 and Supplementary Data. Data analysis. Data generated by this protocol are qPCR Cq values, which are calculated from the PCR amplification curves for each reaction. The Cq values are used to compare the expression of NRO-RNAs between samples by one of several standard methods (i.e., comparison with a standard curve, ∆∆Cq, Pfaffl method [45] [46] [47] . ∆∆Cq is the simplest method that is often suitable in the first instance, especially if the effect size being measured is large. However, this approach assumes that the PCR efficiencies are 100% for both reference and gene-of-interest assays-which is frequently not the case. In contrast, comparing sample Cq values to a standard curve of serially diluted cDNA, or using the Pfaffl method, enables the user to correct for assay PCR efficiencies leading to more accurate transcription quantification. The number of NRO-RNA transcripts is proportional to the transcriptional activity of the corresponding gene. As such, NRO-RT-qPCR can be used to detect relative changes in the transcriptional activity of a gene between experimental samples. Levels of transcription for a gene of interest are normalized to one or more reference genes (the transcription of which is not expected to change) in order to correct for differential sample loading (see 'Reference genes' above). When information about suitable reference genes is lacking, gene-of-interest data can be normalized to a bromouridinecontaining external spike-in control oligonucleotide (Box 1). This normalization strategy assumes that the number of nuclei used and the amount of RNA immunoprecipitated are equal between samples. Variation in the Cq values for the spike-in control reflects the technical error in the RNA extraction and bromouridine immunocapture stages, and it is expected to be minimal. High variation (i.e., replicate Cq s.d. > 1) in the spikein values is indicative that the data may be too noisy to be able to draw meaningful conclusions. If the Cq values for the spike-in control are undetectable or high (>35), the efficiency of bromouridine immunocapture is too low to continue, and further optimization is required. 1| Culture cells as required, depending on the design of the experiment. The optimal quantity of nuclei for NRO is between 1 and 4 million per sample.
2| Collect cells using one of the following methods. For adherent cells, use either mechanical scraping (option A) or cold trypsinzation (option B)
. For suspension cells, follow option C. We have found that, for adherent cells, trypsinization (option B) is generally the most convenient method, as fewer cells remain attached to the plate than with scraping. For some cell types, cell scraping (option A) can lead to loss of cells or nuclei. For cell types that require long trypsinization, scraping is preferable to avoid potential adverse effects of the trypsin treatment on cell metabolism 48 . 
10|
Add 60 µl of transcription buffer reaction buffer cocktail to each nuclei suspension sample from Step 9.
11| (Optional) Add 10 µl of spike-in control oligonucleotide(s) (1 × 10 7 copies per µl stock solution) to each sample. Spike-in controls can be prepared as described in box 1.
12|
Ensure that nuclei are fully resuspended by gentle pipetting.
13|
Incubate the cells at 30 °C for 30 min. Next, proceed immediately to Step 14 to stop the NRO reaction.
extraction of nuclear rna • tIMInG 1.5 h 14| Extract nuclear RNA by one of the following methods. The automated protocol (option A) requires an RNA extraction robot, and it is the most convenient method, as it involves minimal hands-on time, is highly consistent between samples and includes a DNase I treatment step. Alternatively, the column-based protocol (option B) can be performed using common laboratory equipment. Column-based extraction of RNA is rapid, but an additional DNA removal step must be performed and extraction efficiencies may vary between samples. 
Immunoprecipitation of bromouridylated nro-rnas • tIMInG 3 h 16|
Resuspend protein G Dynabeads by repetitive pipetting, and transfer enough beads (30 µl per run-on sample) to a fresh 1.7-ml microcentrifuge tube.
17|
Collect the beads by placing the tube on a magnet and incubating for 3 min at room temperature. Discard the bead storage buffer.
18|
Wash the beads twice with PBST. To perform the wash step, resuspend the beads in 0.5 ml of PBST and then place the tubes on the magnet. Incubate the beads for 3 min and then discard the supernatant.
19|
Resuspend the beads in PBST (volume = 30 µl × number of samples) and prepare 30-µl aliquots of beads into separate 1.7-ml tubes for each NRO reaction.
20| Add 2 µg of anti-BrdU monoclonal antibody to each tube and incubate the tubes on a rotating platform for 10 min at room temperature.
21|
Add 150 µl of blocking buffer to each tube and incubate for 30 min at room temperature.
22|
Capture the beads using the magnet, and then discard the buffer.
23|
Wash the beads twice with 300 µl of PBSTR.
24|
Resuspend the beads in 100 µl of PBSTR.
25|
Incubate NRO-RNA samples from Step 15 at 65 °C for 5 min in a thermal cycler in order to denature any RNA secondary structure, which may reduce the efficiency of antibody binding.
26|
Add an equal volume of NRO-RNA to each tube from Step 24. The amount of RNA added should be within the range of 0.5-8 µg per immunoprecipitation.
27|
Incubate the beads and NRO-RNA samples for 30 min at room temperature on a rotating platform. 33| Vortex for 15 s and then incubate the samples for 10 min at room temperature.
34|
Centrifuge the samples at 13,000g for 10 min at 4 °C. The mixture should have separated into two phases. The top clear layer is the aqueous phase, which contains the RNA.
35|
Carefully aspirate the top (RNA-containing) layer and transfer it to a clean microcentrifuge tube. Take care not to touch the phenolic (red) phase.
36|
Precipitate the nucleic acids by adding 250 µl (0.5× volume) of isopropanol and 20 µg of RNase-free glycogen (1 µl of 20 mg/ml stock) to each sample.  crItIcal step The amount of labeled RNA that is precipitated at this stage is very small, and thus the addition of glycogen (which acts as an inert carrier for nucleic acids) maximizes yield and ensures that a pellet is visible after isopropanol precipitation.
37|
Vortex each sample for 10 s and then incubate the samples for 10 min at room temperature.  crItIcal step If the samples are not adequately mixed, the RNA will not precipitate and the yield will be very low.
38|
Centrifuge the samples at 13,000g for 10 min at 4 °C. The nucleic acids form a white pellet. Carefully remove and discard the supernatant.
39| Wash the pellet with 1 ml (2× volumes) of 70% (vol/vol) ethanol.
40|
Centrifuge the samples at 5,500g for 5 min at 4 °C. Carefully remove and discard the wash.
41|
Pulse-spin the tubes to collect any residual wash solution. Carefully remove and discard the supernatant.
42|
Uncap all the tubes and incubate them for 10 min at room temperature to dry the pellets.
43|
Resuspend each precipitated NRO-RNA pellet in 30 µl of nuclease-free water. Note that at this stage the RNA concentration will be too low to measure by NanoDrop. We have also found that the RNA concentration is typically below the lower limit of detection of the Qubit fluorometer. As a result, sample concentrations are expected to be <0.4 ng/µl and total RNA yields <12 ng.  pause poInt cDNA samples can be stored indefinitely at −20 °C.
Quantitative pcr • tIMInG 3 h  crItIcal Prevent PCR amplicon carryover during preparation of qPCR by using clean gloves and barrier pipette tips, assigning dedicated pre-and post-PCR areas and avoiding opening the plates after run completion.
47|
Prepare the following qPCR cocktail for each sample. Ensure that at least 10% excess cocktail is prepared to account for losses during pipetting. 
48|
Pipette qPCR cocktails onto the qPCR plate. Seal the plate using an optical seal.
49|
Spin the plate at 1,000g for 1 min to collect the liquid at the bottom of the plate. 
50|

Downregulation of nascent transcription
NRO-RT-qPCR can show that a reduction in steady-state mRNA levels is due to a reduction in nascent transcription.
To demonstrate this, we made use of P493-6 cells, which have been engineered to silence transcription from the MYC promoter on the addition of doxycycline (DOX) 50 .
RT-qPCR and western blot analysis showed reduced steady-state MYC mRNA (Fig. 2a) and protein ( Fig. 2b) expression after 24 h of treatment with DOX. NRO on cells cultured in parallel showed that in addition to a reduction in total nuclear RNA content (Fig. 2c , consistent with results in Koberna et al. 40 ) nascent transcription of MYC was also significantly downregulated ( Fig. 2d) in DOX-treated cultures. Correlation between MYC steady-state mRNA levels and nascent transcription is indicative of transcriptional silencing.
upregulation of nascent transcription
Conversely, NRO-RT-qPCR can show that an increase in steady-state mRNA levels is due to an increase in transcriptional activity. To demonstrate this, HCT116 colorectal carcinoma cells were treated with doxorubicin (DOXO). DOXO treatment is known to induce the DNA damage response, which leads to TP53 localizing to the CDKN1A (p21) promoter and activating its transcription 51, 52 . Treatment with DOXO for 24 h increased CDKN1A mRNA (Fig. 2e) and protein ( Fig. 2f) expression by approximately eightfold. NRO was performed on cells cultured in parallel. Total nuclear RNA was reduced by ~40% in DOXO-treated cultures (Fig. 2g) . NRO analysis demonstrated a statistically significant increase in CDKN1A nascent transcription (Fig. 2h) . Correlation between CDKN1A steady-state mRNA levels and nascent transcription is indicative of transcriptional activation.
post-transcriptional silencing
To demonstrate PTGS, we targeted BIRC5 (survivin) by RNAi using a shRNA. RNAi is an endogenous mechanism of post-transcriptional silencing whereby target mRNAs are selectively degraded, whereas transcription is unaffected. Transfection of HE293T cells with an shRNA targeting BIRC5 3′ untranslated region (shBIRC5) resulted in significant downregulation of steady-state mRNA (Fig. 2i) and protein ( Fig. 2j ) expression relative to a nonspecific control shRNA (shNS1). NRO analysis performed on cells cultured in parallel showed no significant change in total nuclear RNA (Fig. 2k) or nascent BIRC5 transcription (Fig. 2l) . A decrease in BIRC5 steady-state mRNA levels in the absence of a change in nascent transcription is indicative of PTGS.
rapid or transient changes in nascent transcription
An advantage of the NRO method is that it can be used to detect changes in transcriptional activity that occur on the order of minutes to hours 19, 20 . In these cases, a change in transcriptional activity may be apparent before the cellular pool of total mRNA has had time to adapt. Consequently, NRO has the power to detect rapid and/or transient changes in transcriptional activity that are inaccessible to steady-state total mRNA analyses. To demonstrate the potential of the present NRO-RT-qPCR protocol to investigate these phenomena, we repressed MYC expression in P493-6 cells (Fig. 3a) and induced CDKN1A expression in HCT116 cells (Fig. 3b) , as described above. Cells were collected at a series of time points after ; **P < 0.01 and ***P < 0.0001. All qPCR data were analyzed using the ∆∆Cq method and internally normalized to GAPDH expression. The mean value of the control group was returned to 1 in each case.
repression or induction, and transcriptional activity was analyzed by NRO-RT-qPCR and steady-state total mRNA levels by conventional RT-qPCR, respectively. In both model systems, a change in transcription was observed before a change in steady-state mRNA expression (Fig. 3a,b) . Repression of MYC transcription by DOX happened rapidly (within minutes). In contrast, induction of CDKN1A was much slower (on the order of hours) as DOXO acts as an indirect inducer.
Distinguishing between transcription initiation and elongation
NRO-RT-qPCR analysis can also be used to distinguish between changes in transcription initiation and elongation (i.e., the release of paused polymerases). To demonstrate this, HCT116 cultures were treated with DOXO for 4 h, such that transcriptional activation had not reached a maximum value. NRO was performed with a limiting concentration of CTP (10 µM, 100-fold less than the other nucleotides) in order to restrict the length of NRO-RNA transcripts. Seven qPCR assays were designed to amplify different regions of the CDKN1A NRO-RNA (Fig. 3c) . After NRO, no specific amplification was observed at the first two exons (primer sets A and B), indicating that it is primarily the short isoforms of CDKN1A that are expressed in HCT116 cells (Fig. 3d) . Furthermore, the level of transcriptional activation was comparable across the entire length of the gene (primer sets C to G), which is suggestive of an increase in transcriptional initiation with a constant rate of elongation. (Enhanced elongation is typified by an increase in signal in the body of the gene relative to the 5′ promoter-proximal part of the gene.) 
